Suresh V Ambudkar

List of Publications by Year
in descending order

233 papers	20,202 citations	12303 69 h-index	11581 135 g-index
236 all docs	236 docs citations	236 times ranked	19180 citing authors

#	Article	IF	Citations
1	A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2). Chemico-Biological Interactions, 2022, 351, 109718.	1.7	4
2	Interaction of A3 adenosine receptor ligands with the human multidrug transporter ABCG2. European Journal of Medicinal Chemistry, 2022, 231, 114103.	2.6	3
3	ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1. Frontiers in Bioscience, 2022, 27, 1.	0.8	3
4	PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study. Molecular Cancer, 2022, 21, 40.	7.9	5
5	The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biomedicine and Pharmacotherapy, 2022, 149, 112922.	2.5	4
6	Polyoxovanadates as new Pâ€glycoprotein inhibitors: insights into the mechanism of inhibition. FEBS Letters, 2022, 596, 381-399.	1.3	3
7	P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhibitor Ensartinib in Cancer Cells. Cancers, 2022, 14, 2341.	1.7	6
8	Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles. Scientific Reports, 2021, 11, 1788.	1.6	17
9	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in Pharmacology, 2021, 12, 620874.	1.6	8
10	Does the ATPâ€bound EQ mutant reflect the preâ€•or postâ€ATP hydrolysis state in the catalytic cycle of human Pâ€glycoprotein (ABCB1)?. FEBS Letters, 2021, 595, 750-762.	1.3	6
11	Characterization of the Lipidome and Biophysical Properties of Membranes from High Five Insect Cells Expressing Mouse P-Glycoprotein. Biomolecules, 2021, 11, 426.	1.8	5
12	Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. International Journal of Molecular Sciences, 2021, 22, 2592.	1.8	9
13	Tetrahydroquinoline/4,5â€Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2). ChemMedChem, 2021, 16, 2686-2694.	1.6	6
14	The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochemical Pharmacology, 2021, 188, 114516.	2.0	21
15	Use of photoimmunoconjugates to characterize ABCB1 in cancer cells. Nanophotonics, 2021, 10, 3049-3061.	2.9	4
16	Branebrutinib (BMS-986195), a Brutonâ€™s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. Frontiers in Cell and Developmental Biology, 2021, 9, 699571.	1.8	3
17	Mechanistic Insights into Photodynamic Regulation of Adenosine 5â€²-Triphosphate-Binding Cassette Drug Transporters. ACS Pharmacology and Translational Science, 2021, 4, 1578-1587.	2.5	5
18	A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo. International Journal of Molecular Sciences, 2021, 22, 12502.	1.8	7

#	Article	IF	Citations
19	Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter. Scientific Reports, 2021, 11, 24150.	1.6	15
20	ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942. Oncogene, 2020, 39, 651-663.	2.6	17
21	The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences, 2020, 21, 238.	1.8	10
22	Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29609-29617.	3.3	28
23	Nonsynonymous Mutations in Linker-2 of the Pdr5 Multidrug Transporter Identify a New RNA Stability Element. G3: Genes, Genomes, Genetics, 2020, 10, 357-369.	0.8	3
24	BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 2502.	1.7	11
25	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro. Frontiers in Oncology, 2020, 10, 700.	1.3	25
26	Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology, 2020, 180, 114137.	2.0	19
27	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 186.	1.7	33
28	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products, 2020, 83, 1461-1472.	1.5	25
29	Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. F1000Research, 2020, 9, 17.	0.8	25
30	MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. American Journal of Cancer Research, 2020, 10, 164-178.	1.4	5
31	Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities. Journal of Investigative Dermatology, 2019, 139, 1985-1992.e10.	0.3	6
32	An A666G mutation in transmembrane helix 5 of the yeast multidrug transporter Pdr5 increases drug efflux by enhancing cooperativity between transport sites. Molecular Microbiology, 2019, 112, 1131-1144.	1.2	7
33	Evidence for the Interaction of A₃ Adenosine Receptor Agonists at the Drug-Binding Site(s) of Human P-glycoprotein (ABCB1). Molecular Pharmacology, 2019, 96, 180-192.	1.0	10
34	Avapritinib: A Selective Inhibitor of KIT and PDGFRÎ± that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Molecular Pharmaceutics, 2019, 16, 3040-3052.	2.3	49
35	Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. Frontiers in Oncology, 2019, 9, 313.	1.3	28
36	Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells. Cancer Letters, 2019, 457, 110-118.	3.2	39

#	Article	IF	Citations
37	Large-scale purification of functional human P-glycoprotein (ABCB1). Protein Expression and Purification, 2019, 159, 60-68.	0.6	18
38	Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1). Drug Metabolism and Disposition, 2019, 47, 1013-1023.	1.7	13
39	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology, 2019, 96, 629-640.	1.0	22
40	The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Cancer Letters, 2019, 445, 34-44.	3.2	28
41	Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer. Cancer Letters, 2019, 442, 104-112.	3.2	33
42	Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Letters, 2019, 440-441, 82-93.	3.2	83
43	ABC Transporter-Mediated Multidrug-Resistant Cancer. Advances in Experimental Medicine and Biology, 2019, 1141, 549-580.	0.8	150
44	ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators. Biochemical Journal, 2019, 476, 3737-3750.	1.7	20
45	Synthesis and characterization of BODIPYâ€FLâ€cyclosporine A as a substrate for both human and mouse multidrug resistanceâ€linked Pâ€glycoprotein. FASEB Journal, 2019, 33, 656.10.	0.2	0
46	Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug/Substrate-Binding Site of P-Glycoprotein. Journal of Medicinal Chemistry, 2018, 61, 834-864.	2.9	25
47	Evidence for the critical role of transmembrane helices 1 and 7 in substrate transport by human P-glycoprotein (ABCB1). PLoS ONE, 2018, 13, e0204693.	1.1	17
48	Novel Potent ABCB1 Modulator, Phenethylisoquinoline Alkaloid, Reverses Multidrug Resistance in Cancer Cell. Molecular Pharmaceutics, 2018, 15, 4021-4030.	2.3	8
49	SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Letters, 2018, 433, 259-272.	3.2	19
50	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochemical Pharmacology, 2018, 155, 316-325.	2.0	16
51	The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines. Cancer Letters, 2018, 434, 81-90.	3.2	7
52	Mapping discontinuous epitopes for MRK-16, UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein. Scientific Reports, 2018, 8, 12716.	1.6	21
53	The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors. Molecular Cancer Therapeutics, 2017, 16, 1021-1030.	1.9	30
54	Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881. Biochemical Pharmacology, 2017, 132, 29-37.	2.0	28

#	Article	IF	Citations
55	Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. Scientific Reports, 2017, 7, 42106.	1.6	10
56	Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells. Molecular Pharmaceutics, 2017, 14, 2368-2377.	2.3	11
57	Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: InÂvitro and inÂvivo study. Cancer Letters, 2017, 396, 145-154.	3.2	56
58	Effects of a detergent micelle environment on P-glycoprotein (ABCB1)-ligand interactions. Journal of Biological Chemistry, 2017, 292, 7066-7076.	1.6	47
59	Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistanceâ€“Linked ATP-Binding Cassette Transporter ABCG2. Drug Metabolism and Disposition, 2017, 45, 1166-1177.	1.7	40
60	Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Letters, 2017, 409, 56-65.	3.2	18
61	Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency. Biochemical Pharmacology, 2017, 143, 53-64.	2.0	29
62	Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. Molecular Pharmaceutics, 2017, 14, 2805-2814.	2.3	24
63	Structures of the Multidrug Transporter P-glycoprotein Reveal Asymmetric ATP Binding and the Mechanism of Polyspecificity. Journal of Biological Chemistry, 2017, 292, 446-461.	1.6	152
64	South Asian Medicinal Compounds as Modulators of Resistance to Chemotherapy and Radiotherapy. Cancers, 2016, 8, 32.	1.7	25
65	Cryo-EM Analysis of the Conformational Landscape of Human P-glycoprotein (ABCB1) During its Catalytic Cycle. Molecular Pharmacology, 2016, 90, 35-41.	1.0	75
66	Screening dietary flavonoids for the reversal of P-glycoprotein-mediated multidrug resistance in cancer. Molecular BioSystems, 2016, 12, 2458-2470.	2.9	70
67	Crystal structure of the antigen-binding fragment of a monoclonal antibody specific for the multidrug-resistance-linked ABC transporter human P-glycoprotein. Acta Crystallographica Section F, Structural Biology Communications, 2016, 72, 636-641.	0.4	7
68	Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell Monolayers. Drug Metabolism and Disposition, 2016, 44, 180-188.	1.7	5
69	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Molecular Pharmacology, 2016, 89, 263-272.	1.0	21
70	Humanâ€“Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1). Biochemistry, 2016, 55, 1010-1023.	1.2	14
71	Drugâ€“protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein. Biochemical Pharmacology, 2016, 101, 40-53.	2.0	81
72	A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDRin vitroandin vivo. Oncotarget, 2015, 6, 39276-39291.	0.8	20

#	Article	IF	Citations
73	Revealing the fate of cell surface human P-glycoprotein (ABCB1): The lysosomal degradation pathway. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 2361-2370.	1.9	27
74	The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Investigational New Drugs, 2015, 33, 300-309.	1.2	22
75	Molecular Basis of the Polyspecificity of P-Glycoprotein (ABCB1). Advances in Cancer Research, 2015, 125, 71-96.	1.9	114
76	Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. Experimental Cell Research, 2015, 336, 318-328.	1.2	22
77	The multidrug transporter Pdr5 on the 25th anniversary of its discovery: an important model for the study of asymmetric ABC transporters. Biochemical Journal, 2015, 467, 353-363.	1.7	56
78	ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. Chinese Journal of Cancer, 2015, 34, 115-20.	4.9	17
79	A Combination of Curcumin with Either Gramicidin or Ouabain Selectively Kills Cells that Express the Multidrug Resistance-Linked ABCG2 Transporter. Biophysical Journal, 2015, 108, 145a.	0.2	0
80	The Inhibitor Ko143 Is Not Specific for ABCG2. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 384-393.	1.3	113
81	Hydrogel-assisted functional reconstitution of human P-glycoprotein (ABCB1) in giant liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 643-653.	1.4	20
82	Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA. PLoS ONE, 2015, 10, e0136396.	1.1	5
83	Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). Future Oncology, 2014, 10, 1827-1841.	1.1	28
84	WHI â€Þ154 enhances the chemotherapeutic effect of anticancer agents in ABCG 2â€overexpressing cells. Cancer Science, 2014, 105, 1071-1078.	1.7	21
85	Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. International Journal of Biochemistry and Cell Biology, 2014, 51, 111-119.	1.2	29
86	Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex. Drug Metabolism and Disposition, 2014, 42, 78-88.	1.7	169
87	Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding Cassette Drug Transporters and BCR-ABL Kinase Using a Three-Dimensional Quantitative Structureâ€“Activity Relationship Approach. Molecular Pharmaceutics, 2014, 11, 2313-2322.	2.3	21
88	A Combination of Curcumin with Either Gramicidin or Ouabain Selectively Kills Cells That Express the Multidrug Resistance-linked ABCG2 Transporter. Journal of Biological Chemistry, 2014, 289, 31397-31410.	1.6	28
89	Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochemical Pharmacology, 2014, 90, 367-378.	2.0	50
90	Design, Synthesis, and Biological Evaluation of (S)â€Valine Thiazoleâ€Derived Cyclic and Noncyclic Peptidomimetic Oligomers as Modulators of Human Pâ€Glycoprotein (ABCB1). ChemBioChem, 2014, 15, 157-169.	1.3	17

#	Article	IF	Citations
91	Evidence for a Molecular Diode-based Mechanism in a Multispecific ATP-binding cassette (ABC) Exporter. Journal of Biological Chemistry, 2014, 289, 26597-26606.	1.6	15
92	MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer. Cancer Research, 2014, 74, 598-608.	0.4	103
93	Design and Synthesis of Human ABCB1 (P-Glycoprotein) Inhibitors by Peptide Coupling of Diverse Chemical Scaffolds on Carboxyl and Amino Termini of (S)-Valine-Derived Thiazole Amino Acid. Journal of Medicinal Chemistry, 2014, 57, 4058-4072.	2.9	51
94	Functional Assay for Characterizing Human P-Glycoprotein Transport using the Pore Forming Peptide Gramicidin A. Biophysical Journal, 2014, 106, 791a.	0.2	0
95	ARRYâ€334543 Reverses Multidrug Resistance by Antagonizing the Activity of ATPâ€Binding Cassette Subfamily G Member 2. Journal of Cellular Biochemistry, 2014, 115, 1381-1391.	1.2	18
96	The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharmaceutica Sinica B, 2014, 4, 105-111.	5.7	48
97	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	0.8	41
98	Saracatinib (AZD0530) is a potent modulator of ABCB1â€mediated multidrug resistance in vitro and in vivo. International Journal of Cancer, 2013, 132, 224-235.	2.3	37
99	The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochemical Pharmacology, 2013, 85, 514-524.	2.0	80
100	Mutations in Intracellular Loops 1 and 3 Lead to Misfolding of Human P-glycoprotein (ABCB1) That Can Be Rescued by Cyclosporine A, Which Reduces Its Association with Chaperone Hsp70. Journal of Biological Chemistry, 2013, 288, 32622-32636.	1.6	21
101	Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 682-686.	1.0	19
102	Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochemical Pharmacology, 2013, 85, 325-334.	2.0	70
103	Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. Biochemical Pharmacology, 2013, 86, 904-913.	2.0	39
104	Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. European Journal of Pharmaceutical Sciences, 2013, 49, 441-450.	1.9	23
105	PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 189-199.	1.1	48
106	The Deviant ATP-binding Site of the Multidrug Efflux Pump Pdr5 Plays an Active Role in the Transport Cycle. Journal of Biological Chemistry, 2013, 288, 30420-30431.	1.6	40
107	Bioluminescent imaging of drug efflux at the bloodâ€“brain barrier mediated by the transporter ABCG2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20801-20806.	3.3	40
108	Human Immunodeficiency Virus Protease Inhibitors Interact with ATP Binding Cassette Transporter 4/Multidrug Resistance Protein 4: A Basis for Unanticipated Enhanced Cytotoxicity. Molecular Pharmacology, 2013, 84, 361-371.	1.0	38

#	Article	IF	Citations
109	The Transmission Interface of the Saccharomyces cerevisiae Multidrug Transporter Pdr5: Val-656 Located in Intracellular Loop 2 Plays a Major Role in Drug Resistance. Antimicrobial Agents and Chemotherapy, 2013, 57, 1025-1034.	1.4	33
110	Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference. PLoS ONE, 2013, 8, e60334.	1.1	42
111	Multidrug Resistance in Cancer: A Tale of ABC Drug Transporters. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 1-34.	0.1	7
112	The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions. PLoS ONE, 2013, 8, e71266.	1.1	28
113	Multiple Transport-Active Binding Sites Are Available for a Single Substrate on Human P-Glycoprotein (ABCB1). PLoS ONE, 2013, 8, e82463.	1.1	86
114	Ceramide Glycosylation by Glucosylceramide Synthase Selectively Maintains the Properties of Breast Cancer Stem Cells. Journal of Biological Chemistry, 2012, 287, 37195-37205.	1.6	64
115	The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2. Molecular Cancer Therapeutics, 2012, 11, 2033-2044.	1.9	81
116	Use of Baculovirus BacMam Vectors for Expression of ABC Drug Transporters in Mammalian Cells. Drug Metabolism and Disposition, 2012, 40, 304-312.	1.7	41
117	Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo. Molecular Pharmacology, 2012, 82, 47-58.	1.0	87
118	Multidrug Resistanceâ€“Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. Clinical Cancer Research, 2012, 18, 3197-3206.	3.2	60
119	Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resistance Updates, 2012, 15, 70-80.	6.5	143
120	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochemical Pharmacology, 2012, 84, 766-774.	2.0	22
121	BBA, a Derivative of 23-Hydroxybetulinic Acid, Potently Reverses ABCB1-Mediated Drug Resistancein Vitroandin Vivo. Molecular Pharmaceutics, 2012, 9, 3147-3159.	2.3	43
122	Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance. Journal of Nutritional Biochemistry, 2012, 23, 76-84.	1.9	38
123	The Pim Kinase Inhibitor SGI-1776 Chemosensitizes Multidrug Resistant Cells by Both Inhibiting Drug Transport by ABCB1 and ABCG2 and Decreasing ABCB1 and ABCG2 Surface Expression On Cells That Overexpress Pim-1.. Blood, 2012, 120, 2462-2462.	0.6	0
124	Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18708-18713.	3.3	381
125	Biochemical Mechanism of Modulation of Human P-glycoprotein by Stemofoline. Planta Medica, 2011, 77, 1990-1995.	0.7	28
126	Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions. Molecular Pharmaceutics, 2011, 8, 2080-2088.	2.3	31

#	Article	IF	Citations
127	The â€œSpecificâ€•P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2). ACS Chemical Neuroscience, 2011, 2, 82-89.	1.7	153
128	The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter. PLoS ONE, 2011, 6, e19329.	1.1	71
129	Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy. Current Pharmaceutical Biotechnology, 2011, 12, 609-620.	0.9	150
130	In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. Biochemical Pharmacology, 2011, 82, 1562-1571.	2.0	17
131	Synthesis and Characterization of a BODIPY Conjugate of the BCR-ABL Kinase Inhibitor Tasigna (Nilotinib): Evidence for Transport of Tasigna and Its Fluorescent Derivative by ABC Drug Transporters. Molecular Pharmaceutics, 2011, 8, 1292-1302.	2.3	49
132	Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance. Cancer Research, 2011, 71, 3029-3041.	0.4	157
133	A Combination of Low Doses of Curcumin and Gramicidin Selectively kills Cancer Cells that Express Multidrug Resistanceâ€linked ABCG2 Transporter. FASEB Journal, 2011, 25, 966.4.	0.2	0
134	Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2010, 80, 1497-1506.	2.0	57
135	Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib. Drug Metabolism and Disposition, 2010, 38, 1371-1380.	1.7	202
136	Dependence of Multidrug Resistance Protein-Mediated Cyclic Nucleotide Efflux on the Background Sodium Conductance. Molecular Pharmacology, 2010, 77, 270-279.	1.0	24
137	The Skin Cancer Chemotherapeutic Agent Ingenol-3-Angelate (PEP005) Is a Substrate for the Epidermal Multidrug Transporter (ABCB1) and Targets Tumor Vasculature. Cancer Research, 2010, 70, 4509-4519.	0.4	77
138	The Signaling Interface of the Yeast Multidrug Transporter Pdr5 Adopts a Cis Conformation, and There Are Functional Overlap and Equivalence of the Deviant and Canonical Q-Loop Residues. Biochemistry, 2010, 49, 4440-4449.	1.2	41
139	Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Research, 2010, 70, 7981-7991.	0.4	297
140	Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. Journal of the National Cancer Institute, 2010, 102, 1637-1652.	3.0	241
141	Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. Journal of Clinical Investigation, 2010, 120, 2953-2966.	3.9	393
142	Curcumin Modulates Efflux Mediated by Yeast ABC Multidrug Transporters and Is Synergistic with Antifungals. Antimicrobial Agents and Chemotherapy, 2009, 53, 3256-3265.	1.4	96
143	Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition, 2009, 37, 359-365.	1.7	209
144	Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Molecular Cancer Therapeutics, 2009, 8, 2057-2066.	1.9	41

#	Article	IF	Citations
145	Identification of Compounds that Correlate with ABCG2 Transporter Function in the National Cancer Institute Anticancer Drug Screen. Molecular Pharmacology, 2009, 76, 946-956.	1.0	26
146	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochemical Pharmacology, 2009, 77, 781-793.	2.0	69
147	Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochemical Pharmacology, 2009, 78, 355-364.	2.0	26
148	Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in Mice. Pharmaceutical Research, 2009, 26, 480-487.	1.7	128
149	Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemotherapy and Pharmacology, 2009, 64, 575-583.	1.1	25
150	Structure of a multidrug transporter. Nature Biotechnology, 2009, 27, 546-547.	9.4	69
151	Botryllamides: Natural Product Inhibitors of ABCG2. ACS Chemical Biology, 2009, 4, 637-647.	1.6	49
152	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU International, 2008, 102, 1694-1699.	1.3	22
153	Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1Â®. Biochemical Pharmacology, 2008, 75, 1302-1312.	2.0	143
154	Development of inhibitors of ATP-binding cassette drug transporters â€“ present status and challenges. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 205-223.	1.5	225
155	Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima. Journal of Molecular Biology, 2008, 383, 281-291.	2.0	230
156	Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research, 2008, 68, 7905-7914.	0.4	362
157	Mutations Define Cross-talk between the N-terminal Nucleotide-binding Domain and Transmembrane Helix-2 of the Yeast Multidrug Transporter Pdr5. Journal of Biological Chemistry, 2008, 283, 35010-35022.	1.6	60
158	The glucoseâ€6â€phosphate transporter is a phosphateâ€linked antiporter deficient in glycogen storage disease type Ib and Ic. FASEB Journal, 2008, 22, 2206-2213.	0.2	52
159	Relationship Between Drugs and Functional Activity of Various Mammalian P-Glycoproteins (ABCB1). Mini-Reviews in Medicinal Chemistry, 2008, 8, 193-200.	1.1	40
160	Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies. Current Molecular Pharmacology, 2008, 1, 93-105.	0.7	229
161	Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. Molecular Cancer Therapeutics, 2007, 6, 1877-1885.	1.9	57
162	Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistanceâ€linked ABCG2 transporter. Molecular Cancer Therapeutics, 2007, 6, 3287-3296.	1.9	89

#	Article	IF	Citations
163	ABC Drug Transporters as Molecular Targets for the Prevention of Multidrug Resistance and Drug-Drug Interactions. Current Drug Delivery, 2007, 4, 324-333.	0.8	59
164	About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Molecular Cancer Therapeutics, 2007, 6, 13-23.	1.9	132
165	Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer. Cancer Research, 2007, 67, 9609-9612.	0.4	219
166	New inhibitors of ABCG2 identified by high-throughput screening. Molecular Cancer Therapeutics, 2007, 6, 3271-3278.	1.9	57
167	The yeast Pdr5p multidrug transporter: How does it recognize so many substrates?. Biochemical and Biophysical Research Communications, 2007, 356, 1-5.	1.0	53
168	A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity. Science, 2007, 315, 525-528.	6.0	2,230
169	The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistanceâ€“linked ATP binding cassette drug transporter ABCG2. Molecular Cancer Therapeutics, 2007, 6, 3279-3286.	1.9	60
170	Catalytic Cycle of ATP Hydrolysis by P-Glycoprotein:â€‰ Evidence for Formation of the EÂ·S Reaction Intermediate with ATP-Î³-S, a Nonhydrolyzable Analogue of ATP. Biochemistry, 2007, 46, 13787-13799.	1.2	95
171	Complete Inhibition of the Pdr5p Multidrug Efflux Pump ATPase Activity by Its Transport Substrate Clotrimazole Suggests that GTP as Well as ATP May Be Used as an Energy Source. Biochemistry, 2007, 46, 13109-13119.	1.2	52
172	Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2â€“Mediated Drug Resistance. Cancer Research, 2007, 67, 11012-11020.	0.4	280
173	Sipholenol A, a marineâ€derived sipholane triterpene, potently reverses Pâ€glycoprotein (ABCB1)â€mediated multidrug resistance in cancer cells. Cancer Science, 2007, 98, 1373-1380.	1.7	56
174	Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemotherapy and Pharmacology, 2007, 60, 179-188.	1.1	75
175	Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Molecular and Cellular Biochemistry, 2007, 296, 85-95.	1.4	202
176	Genomics and the mechanism of P-glycoprotein (ABCB1). Journal of Bioenergetics and Biomembranes, 2007, 39, 481-487.	1.0	76
177	ATPâ€driven dimerization of nucleotide binding domains, asymmetric occlusion of one nucleotide and ADPâ€driven disassembly of the occluded state are important reaction intermediates of the Pâ€glycoprotein transport cycle. FASEB Journal, 2007, 21, A242.	0.2	0
178	The Conserved Tyrosine Residues 401 and 1044 in ATP Sites of Human P-Glycoprotein Are Critical for ATP Binding and Hydrolysis:â€‰ Evidence for a Conserved Subdomain, the A-Loop in the ATP-Binding Cassette. Biochemistry, 2006, 45, 7605-7616.	1.2	56
179	Modulation of the function of the multidrug resistanceâ€“linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Molecular Cancer Therapeutics, 2006, 5, 1995-2006.	1.9	116
180	Comparison of Drug Transporter Levels in Normal Colon, Colon Cancer, and Caco-2 Cells:â€‰ Impact on Drug Disposition and Discovery. Molecular Pharmaceutics, 2006, 3, 87-93.	2.3	45

#	Article	IF	Citations
181	The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Letters, 2006, 580, 1049-1055.	1.3	146
182	Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemotherapy and Pharmacology, 2006, 57, 376-388.	1.1	100
183	The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). European Journal of Pharmaceutical Sciences, 2006, 27, 392-400.	1.9	196
184	Exploiting Reaction Intermediates of the ATPase Reaction to Elucidate the Mechanism of Transport by P-glycoprotein (ABCB1). Journal of Biological Chemistry, 2006, 281, 26501-26511.	1.6	39
185	Selective Toxicity of NSC73306 in MDR1-Positive Cells as a New Strategy to Circumvent Multidrug Resistance in Cancer. Cancer Research, 2006, 66, 4808-4815.	0.4	162
186	Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Molecular Cancer Therapeutics, 2006, 5, 2459-2467.	1.9	60
187	Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and) Tj ETQq1 1 0.784314 rgBT /O	2.2	141
188	Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. Biochemical Pharmacology, 2005, 70, 500-510.	2.0	61
189	Nonequivalence of the Nucleotide Binding Domains of the ArsA ATPase. Journal of Biological Chemistry, 2005, 280, 9921-9926.	1.6	10
190	Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Molecular BioSystems, 2005, 1, 127.	2.9	90
191	A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). Trends in Pharmacological Sciences, 2005, 26, 385-387.	4.0	86
192	Multidrug Resistance Protein 4 (ABCC4)-mediated ATP Hydrolysis. Journal of Biological Chemistry, 2004, 279, 48855-48864.	1.6	49
193	Substitution of threonine-1351 in the multidrug transporter Cdr1p of Candida albicans results in hypersusceptibility to antifungal agents and threonine-1351 is essential for synergic effects of calcineurin inhibitor FK520. Journal of Antimicrobial Chemotherapy, 2004, 54, 38-45.	1.3	23
194	The Molecular Basis of the Action of Disulfiram as a Modulator of the Multidrug Resistance-Linked ATP Binding Cassette Transporters MDR1 (ABCB1) and MRP1 (ABCC1). Molecular Pharmacology, 2004, 65, 675-684.	1.0	91
195	Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans. Biochemical and Biophysical Research Communications, 2004, 322, 520-525.	1.0	53
196	VAMP2-Dependent Exocytosis Regulates Plasma Membrane Insertion of TRPC3 Channels and Contributes to Agonist-Stimulated Ca2+ Influx. Molecular Cell, 2004, 15, 635-646.	4.5	185
197	P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.	2.6	956
198	Studies with Novel Pdr5p Substrates Demonstrate a Strong Size Dependence for Xenobiotic Efflux. Journal of Biological Chemistry, 2003, 278, 5963-5969.	1.6	77

#	Article	IF	Citations
199	Functional Characterization of Candida albicans ABC Transporter Cdr1p. Eukaryotic Cell, 2003, 2, 1361-1375.	3.4	136
200	Transport Activity and Surface Expression of the Na+-Ca2+ Exchanger NCX1 Are Inhibited by the Immunosuppressive Agent Cyclosporin A and by the Nonimmunosuppressive Agent PSC833. Journal of Biological Chemistry, 2002, 277, 2505-2510.	1.6	14
201	Elf1p, a Member of the ABC Class of ATPases, Functions as a mRNA Export Factor in Schizosacchromyces pombe. Journal of Biological Chemistry, 2002, 277, 33580-33589.	1.6	22
202	Importance of the Conserved Walker B Glutamate Residues, 556 and 1201, for the Completion of the Catalytic Cycle of ATP Hydrolysis by Human P-glycoprotein (ABCB1). Biochemistry, 2002, 41, 13989-14000.	1.2	99
203	Evidence for the Role of Glycosylation in Accessibility of the Extracellular Domains of Human MRP1 (ABCC1). Biochemistry, 2002, 41, 10123-10132.	1.2	52
204	Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochemical Pharmacology, 2002, 64, 573-582.	2.0	274
205	Synthesis and analysis of polyethylene glycol linked P-glycoprotein-specific homodimers based on (â^')-stipiamide. Tetrahedron Letters, 2001, 42, 3819-3822.	0.7	11
206	Overview: ABC transporters and human disease. Journal of Bioenergetics and Biomembranes, 2001, 33, 453-458.	1.0	304
207	The mechanism of action of multidrug-resistance-linked P-glycoprotein. Journal of Bioenergetics and Biomembranes, 2001, 33, 481-491.	1.0	154
208	Characterization of the Catalytic Cycle of ATP Hydrolysis by Human P-glycoprotein. Journal of Biological Chemistry, 2001, 276, 11653-11661.	1.6	128
209	Functionally Similar Vanadate-induced 8-Azidoadenosine 5â€²-[Î±-32P]Diphosphate-trapped Transition State Intermediates of Human P-glycoprotein Are Generated in the Absence and Presence of ATP Hydrolysis. Journal of Biological Chemistry, 2001, 276, 21199-21208.	1.6	30
210	Evidence for the Vectorial Nature of Drug (Substrate)-stimulated ATP Hydrolysis by Human P-glycoprotein. Journal of Biological Chemistry, 2001, 276, 33301-33304.	1.6	19
211	Correlation between Steady-state ATP Hydrolysis and Vanadate-induced ADP Trapping in Human P-glycoprotein. Journal of Biological Chemistry, 2001, 276, 8657-8664.	1.6	92
212	Synthesis and preliminary analysis of a P-glycoprotein-specific [3H]-benzophenone photoaffinity label based on (â^')-stipiamide. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2275-2278.	1.0	12
213	Workshop on ABC Transporters and Human Diseases. Drug Resistance Updates, 2000, 3, 51-54.	6.5	8
214	The Synthesis and Evaluation of a Solution Phase Indexed Combinatorial Library of Non-Natural Polyenes for Reversal of P-Glycoprotein Mediated Multidrug Resistance. Journal of Organic Chemistry, 2000, 65, 4973-4983.	1.7	31
215	BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER. Annual Review of Pharmacology and Toxicology, 1999, 39, 361-398.	4.2	1,940
216	Human P-Glycoprotein Exhibits Reduced Affinity for Substrates during a Catalytic Transition State. Biochemistry, 1998, 37, 5010-5019.	1.2	245

#	Article	IF	Citations
217	Contribution to Substrate Specificity and Transport of Nonconserved Residues in Transmembrane Domain 12 of Human P-Glycoproteinâ€. Biochemistry, 1998, 37, 16400-16409.	1.2	80
218	Structural Flexibility of the Linker Region of Human P-Glycoprotein Permits ATP Hydrolysis and Drug Transport. Biochemistry, 1998, 37, 13660-13673.	1.2	99
219	[37] Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods in Enzymology, 1998, 292, 504-514.	0.4	178
220	Mechanism of Action of Human P-glycoprotein ATPase Activity. Journal of Biological Chemistry, 1998, 273, 16631-16634.	1.6	111
221	[36] Purification and reconstitution of human P-glycoprotein. Methods in Enzymology, 1998, 292, 492-504.	0.4	33
222	[23] Photoaffinity labeling of human P-glycoprotein: Effect of modulator interaction and ATP hydrolysis on substrate binding. Methods in Enzymology, 1998, 292, 317-328.	0.4	18
223	Relation Between the Turnover Number for Vinblastine Transport and for Vinblastine-stimulated ATP Hydrolysis by Human P-glycoprotein. Journal of Biological Chemistry, 1997, 272, 21160-21166.	1.6	169
224	P-glycoprotein and multidrug resistance. Current Opinion in Genetics and Development, 1996, 6, 610-617.	1.5	511
225	Characterization of Phosphorylation-defective Mutants of Human P-glycoprotein Expressed in Mammalian Cells. Journal of Biological Chemistry, 1996, 271, 1708-1716.	1.6	160
226	Purification and reconstitution of functional human P-glycoprotein. Journal of Bioenergetics and Biomembranes, 1995, 27, 23-29.	1.0	46
227	Heterologous expression systems for P-glycoprotein:E. coli, yeast, and baculovirus. Journal of Bioenergetics and Biomembranes, 1995, 27, 43-52.	1.0	48
228	Effects of phosphorylation of P-glycoprotein on multidrug resistance. Journal of Bioenergetics and Biomembranes, 1995, 27, 53-61.	1.0	65
229	Functional reconstitution of prokaryote and eukaryote membrane proteins. Archives of Biochemistry and Biophysics, 1989, 269, 1-10.	1.4	77
230	[43] Anion exchange in bacteria: Reconstitution of phosphate: Hexose 6-phosphate antiport from Streptococcus lactis. Methods in Enzymology, 1986, 125, 558-563.	0.4	23
231	Ion Extrusion Systems in Bacteria. Annals of the New York Academy of Sciences, 1985, 456, 235-244.	1.8	11
232	Anion Exchange in Bacteria Variable. Stoichiometry of Phosphate: Sugar 6-Phosphate Antiport. Annals of the New York Academy of Sciences, 1985, 456, 245-247.	1.8	2
233	Reconstitution of phosphate-linked antiport from Streptococcus,lactis. Biochemical and Biophysical Research Communications, 1985, 129, 568-575.	1.0	8